Loading
NASDAQHealthcareBiotechnology
Latest quote
$14.99
−$1.01 · -6.31%
Bambusa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It engages in developing a portfolio of next-generation, multi-targeting medicines designed to transform patient care across chronic immunology and inflammation diseases. The company was founded by Shan Shan Xu, Thang Ho, and Helmut Jeggle on March 14, 2024 and is headquartered in Boston, MA.
Previous close
$14.99
−$1.01 · -6.31%
Regular session · ET · Market data may be delayed.
Bambusa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It engages in developing a portfolio of next-generation, multi-targeting medicines designed to transform patient care across chronic immunology and inflammation diseases. The company was founded by Shan Shan Xu, Thang Ho, and Helmut Jeggle on March 14, 2024 and is headquartered in Boston, MA.
Day range
Current $14.99
52-week range
Current $14.99
Regular session · ET · Market data may be delayed.
Bambusa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It engages in developing a portfolio of next-generation, multi-targeting medicines designed to transform patient care across chronic immunology and inflammation diseases. The company was founded by Shan Shan Xu, Thang Ho, and Helmut Jeggle on March 14, 2024 and is headquartered in Boston, MA.
Day range
Current $14.99
52-week range
Current $14.99
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
